Introduction
Schizophrenia is associated with substantial cognitive dysfunction (Gold & Harvey, Reference Gold and Harvey1993; Heinrichs & Zakzanis, Reference Heinrichs and Zakzanis1998; Bora et al. Reference Bora, Yücel and Pantelis2010). Neurocognitive deficits are persistent characteristics of schizophrenia throughout the illness and are predictors of level of functioning (Green, Reference Green1996; Bora et al. Reference Bora, Yücel and Pantelis2010; Kahn & Keefe, Reference Kahn and Keefe2013). Several studies have provided evidence indicating that cognitive and intellectual deficits are evident early in neurodevelopment, well before the onset of psychosis (Fuller et al. Reference Fuller, Nopoulos, Arndt, O'Leary, Ho and Andreasen2002; Reichenberg et al. Reference Reichenberg, Caspi, Harrington, Houts, Keefe, Murray, Poulton and Moffitt2010; Kahn & Keefe, Reference Kahn and Keefe2013). Evidence also suggests that cognitive deficits are stable at follow-up in both chronic and early years of the illness even though performance of schizophrenia patients might improve less than healthy controls at follow-up (Szöke et al. Reference Szöke, Trandafir, Dupont, Méary, Schürhoff and Leboyer2008; Bora & Murray, Reference Bora and Murray2013; Hedman et al. Reference Hedman, van Haren, van Baal, Kahn and Hulshoff Pol2013). Neurodevelopmental theories argue that schizophrenia is related to genetic and non-genetic risk factors leading to abnormal development of the brain that can be associated with problems in acquiring cognitive abilities throughout development (Weinberger, Reference Weinberger, Nasrallah and Weinberger1986; Murray & Lewis, Reference Murray and Lewis1987), and that neurodevelopmental abnormality can be considered as the source of most of the cognitive deficits observed in adults with schizophrenia. However, one of the challenges of the neurodevelopmental model is that both timing of the emergence and level of severity of functional deficits are variable and these deficits are not always apparent before the illness. Although some patients with schizophrenia have a clear history of pre-morbid intellectual difficulties from childhood and have low functioning throughout their life, many others experience functional decline during prodrome or early years of the illness after seemingly normal early development (Bilder et al. Reference Bilder, Lipschutz-Broch, Reiter, Geisler, Mayerhoff and Lieberman1992; Kelley et al. Reference Kelley, Gilbertson, Mouton and van Kammen1992; Doody et al. Reference Doody, Johnstone, Sanderson, Owens and Muir1998; Addington & Addington, Reference Addington and Addington2005; Morgan et al. Reference Morgan, Leonard, Bourke and Jablensky2008; Foussias & Remington, Reference Foussias and Remington2010; Strauss et al. Reference Strauss, Allen, Miski, Buchanan, Kirkpatrick and Carpenter2012). It is also evident that some chronic and older-age patients with schizophrenia have very significant functional deficits compared to their level of functioning in earlier years of the illness (Davidson et al. Reference Davidson, Harvey, Powchik, Parrella, White, Knobler, Losonczy, Keefe, Katz and Frecska1995; Harvey & Davidson, Reference Harvey, Davidson and Davis2002). Some of these patients are not able to live independently and some have functional deficits comparable to dementia. These observations suggest that neurodegenerative or neuroprogressive changes lead to the onset of illness, and cognitive and functional decline in schizophrenia (Feinberg, Reference Feinberg1982–1983; Wyatt, Reference Wyatt1991; Keshavan et al. Reference Keshavan, Anderson and Pettegrew1994; Liebermann, Reference Lieberman1999; Perkins et al. Reference Perkins, Gu, Boteva and Lieberman2005).
Another key issue to address is the nature of the relationship between pre-morbid cognitive deficits and schizophrenia. It could be argued that these cognitive deficits are specific neurodevelopmental substrates and early signs of schizophrenia (Kahn & Keefe, Reference Kahn and Keefe2013), or they might be markers of a range of developmental abnormalities that increase the risk of developing schizophrenia.
In this Editorial, I review the developmental course of cognitive impairment in schizophrenia and then explore the relationship between neurodevelopmental cognitive abnormality and functional decline later in life. The evidence regarding the course of the cognitive abilities in non-neurodevelopmental (i.e. neurodegenerative such as Huntington disorder, metachromatic leukodystrophy frontotemporal dementia) conditions that can sometimes initially mimic schizophrenia are not reviewed here.
Developmental course of cognitive impairment in schizophrenia
Earlier accounts of neurodevelopmental theory regarded schizophrenia as the outcome of a developmental fixed ‘lesion’ occurring most commonly in the second trimester of intrauterine life (Weinberger, Reference Weinberger, Nasrallah and Weinberger1986). Cognitive deficits were considered a consequence of this ‘static encephalopathy’. However, neurodevelopment is an extended process. Some aspects of normal cortical development, such as proliferation and migration, occur mostly during the prenatal life; other developmental processes (arborization and myelination) continue at least through the first two post-natal decades (Catts et al. Reference Catts, Fung, Long, Joshi, Vercammen, Allen, Fillman, Rothmond, Sinclair, Tiwari, Tsai, Weickert and Shannon Weickert2013). In accordance with neurodevelopment, some basic cognitive functions, mostly crystallized skills, typically develop during the early years of postnatal life, and the development of complex executive functions and other fluid skills are the outcome of protracted development well into early adulthood (Levin et al. Reference Levin, Culhane, Hartmann, Evankovich, Mattson, Harward, Ringolz, Ewing-Cobbs and Fletcher1991; Anderson et al. Reference Anderson, Anderson, Northam, Jacobs and Catroppa2001; Brocki & Bohlin, Reference Brocki and Bohlin2004). Cognitive dysfunction in schizophrenia can be better conceptualized as the outcome of aberrant neurodevelopment continuing throughout the first two to three decades of life.
Levels of severity of neurodevelopmental abnormality and age when cognitive deficits become apparent
One of the key questions for the field of neuropsychology of schizophrenia has been: ‘When precisely do cognitive problems begin in people with schizophrenia?’ In reality, the time when cognitive deficits become apparent is variable across patients. The level of severity of underlying neurodevelopmental impairment influences both the degree of cognitive deficits and the time range when cognitive dysfunction can be detected with traditional neuropsychological batteries. In individuals who have more severe underlying neurodevelopmental abnormality, cognitive dysfunction would be apparent from early childhood. Several research findings support the existence of such early cognitive deficits in some people with schizophrenia (Doody et al. Reference Doody, Johnstone, Sanderson, Owens and Muir1998; Morgan et al. Reference Morgan, Leonard, Bourke and Jablensky2008; Reichenberg et al. Reference Reichenberg, Caspi, Harrington, Houts, Keefe, Murray, Poulton and Moffitt2010; Khandaker et al. Reference Khandaker, Barnett, White and Jones2011; Dickson et al. Reference Dickson, Laurens, Cullen and Hodgins2012; Schulz et al. Reference Schulz, Sundin, Leask and Done2014). Pre-morbid intelligence quotient (IQ) deficits and learning difficulties in childhood and adolescence precede adult schizophrenia. Current evidence suggests that individuals who develop adult schizophrenia exhibit an IQ deficit (approximately 0.5 standard deviation) in their childhood (Khandaker et al. Reference Khandaker, Barnett, White and Jones2011; Dickson et al. Reference Dickson, Laurens, Cullen and Hodgins2012). Childhood-onset intellectual disabilities are over-represented in schizophrenia samples compared to controls and psychosis is more prevalent in people with mental retardation than in the general population (Doody et al. Reference Doody, Johnstone, Sanderson, Owens and Muir1998; Morgan et al. Reference Morgan, Leonard, Bourke and Jablensky2008).
However, the effect size of pre-morbid abnormalities in schizophrenia is fairly small (for d = 0.5, 67% overlap with controls), suggesting that cognitive deficits are not detected early in most patients. More often, neurodevelopmental abnormalities in schizophrenia would be more moderate and cognitive dysfunction would manifest as a failure to acquire more advanced cognitive functions in the second decade following seemingly normal neurodevelopment in early childhood. These individuals would only struggle as the demands of academic and social environments get complicated in later years. It is important to note that a subgroup of schizophrenia patients have no cognitive impairment even in adulthood (MacCabe et al. Reference MacCabe, Brébion, Reichenberg, Ganguly, McKenna, Murray and David2012), suggesting that neurodevelopmental abnormality is much milder in other patients.
Course of neurodevelopmental cognitive deficits
The course of development of cognitive abilities (growth curves) in the first two to three decades of life can supply important information for the neurodegenerative/neurodevelopmental debate in schizophrenia (Testa & Pantelis, Reference Testa, Pantelis, Wood, Allen and Pantelis2009). If schizophrenia is a neurodevelopmental condition, problems in acquisition of cognitive abilities (developmental lag or arrest) during development are expected. By contrast, neurodegeneration would be associated with pre-morbid or post-onset loss of acquired skills at follow-up. Recent evidence provides important insights into the developmental course of these pre-morbid cognitive deficits after the first few years of the life. For example, the Dunedin study of a longitudinal cohort of 1037 males and females clearly demonstrated that deficits in several cognitive domains, including verbal and visual acquisition and conceptualization, were already evident at age 7 years and remained stable at age 13 years (Reichenberg et al. Reference Reichenberg, Caspi, Harrington, Houts, Keefe, Murray, Poulton and Moffitt2010). However, evidence suggests that individuals who develop adult schizophrenia have slower development (developmental lag) in other cognitive abilities during puberty and adolescence. In the Dunedin study, children between the ages of 7 and 13 years exhibited developmental lag on tests indexing visuospatial problem solving, processing speed and attention. Importantly, early verbal deficits significantly predicted later developmental lag in working memory and processing speed. Findings of a recent study reporting cognitive changes between ages 13 and 28 years in the Dunedin sample suggest that a similar pattern of slower cognitive development after age 13 continues in individuals who developed schizophrenia (Meier et al. Reference Meier, Caspi, Reichenberg, Keefe, Fisher, Harrington, Houts, Poulton and Moffitt2014). There is also some evidence for association between relative IQ decline (developmental lag) between ages 4 and 7 and adult-onset schizophrenia (Kremen et al. Reference Kremen, Buka, Seidman, Goldstein, Koren and Tsuang1998). A recent study (MacCabe et al. Reference MacCabe, Wicks, Löfving, David, Berndtsson, Gustafsson, Allebeck and Dalman2013) showed that the relative decline in several cognitive domains (especially verbal ability) between ages 13 and 18 was predictive of psychotic disorder in adulthood (mean age of first hospitalization). In all of these studies, ‘relative decline’ was indicating a problem in acquisition of cognitive abilities (developmental lag or arrest) rather than real decline in raw scores, as in both studies tests at follow-up were age corrected or included more challenging items (Bora, Reference Bora2014). These findings do not support the idea of pre-morbid cognitive decline in schizophrenia. However, other authors, based on cross-sectional comparison of cognitive studies in ultra-high risk (UHR) to psychosis, first-episode psychosis (FEP) and schizophrenia, have suggested that cognitive decline might occur later, around the time psychotic symptoms develop. Nevertheless, follow-up studies in UHR and FEP have clearly rejected this suggestion (Bora & Murray, Reference Bora and Murray2013).
The evidence reviewed above suggests that cognitive deficits are evident in young children who develop adult schizophrenia; these patients gradually fall behind even further, compared to normal controls, in some cognitive abilities throughout development. A similar pattern of developmental lag in the background of early cognitive dysfunction has been reported in other conditions characterized by low brain reserve, such as Fragile X syndrome, autism and velocardiofacial syndrome. For example, in Fragile X syndrome, studies found slower gain in cognitive development in adolescence leading to a relative decline in standardized scores such as IQ; this abnormal neurodevelopment is related to aberrant frontal lobe maturation in adolescents (Hall et al. Reference Hall, Burns, Lightbody and Reiss2008; Bray et al. Reference Bray, Hirt, Jo, Hall, Lightbody, Walter, Chen, Patnaik and Reiss2011). It is not surprising that aberrant early neurodevelopment has a negative impact on later phases of cognitive maturation, as more advanced cognitive skills depend on the integrity of basic cognitive processes and the negative impact of many genetic abnormalities do not need to be restricted to early childhood as they do play a role in neurodevelopment throughout life.
Neurodevelopmental cognitive impairment and psychosis
The findings reviewed above suggest that, with regard to the nature of the relationship between pre-morbid cognitive deficits and schizophrenia, neurodevelopmental cognitive abnormalities are not simple co-morbidities to schizophrenia in the large majority of the cases given the high prevalence of such problems in schizophrenia compared to healthy controls. Cognitive dysfunction is robustly associated with, but not necessary for, developing psychosis. The level of neurodevelopmental cognitive deficits is largely variable and a sizeable minority of schizophrenia patients have preserved cognitive abilities (MacCabe et al. Reference MacCabe, Brébion, Reichenberg, Ganguly, McKenna, Murray and David2012). It is also important to note that only a subset of individuals who have such neurodevelopmental abnormalities would develop psychosis. Clearly, most of these findings are non-specific and are not necessarily indicators for the development of psychotic symptoms. These cognitive deficits should be considered as manifestations of a heterogeneous group of developmental abnormalities with different, but mostly yet unknown, genetic and other neurodevelopmental etiological factors and serve as a risk factor to the development of psychosis. However, most people with such abnormalities would never develop psychotic symptoms.
This does not mean that psychosis has no common neurobiological substrate or associated specific subtle cognitive dysfunction. It is likely that different developmental syndromes increase the risk of psychosis by their converging effect on a much more limited neural network. However, only a small fraction of findings observed in patients should be related to the schizophrenic syndrome. Nevertheless, we do not know what these specific deficits are and how to detect them. It is very unlikely that traditional neuropsychological test batteries will be able to reliably detect such subtle but specific psychosis-related deficits.
Neurodevelopmental cognitive abnormality and functional decline later in life
Neurodevelopmental cognitive deficits contribute to pre-morbid functioning levels and these functional difficulties become more pronounced as academic and social demands increase during adolescence and early adulthood, overlapping with years of prodrome and the early post-onset period. However, not all functional decline should be considered as an outcome of cognitive dysfunction in schizophrenia. The frequency and intensity of episodes, residual symptoms and social defeat are among the other factors that contribute to functional decline in schizophrenia. I also argue that interaction between neurodevelopmental cognitive dysfunction and other factors, including negative symptoms, aging, antipsychotics and medical co-morbidities, are the main factors for post-onset functional decline in schizophrenia.
Neurodevelopment, cognitive reserve and functional decline
Neurodevelopmental abnormality and cognitive reserve are related, and are important concepts in understanding the functional decline observed later in life (Satz et al. Reference Satz1993; Stern, Reference Stern2002, Reference Stern2012). Schizophrenia-related neurodevelopmental abnormalities have a profound negative impact on brain and cognitive reserve. Brain reserve is the brain's resilience, its ability to cope with increasing damage while still functioning adequately, and it depends on the structural integrity of the neural system (hardware) and is mostly determined by genetic and neurodevelopmental factors. Therefore, the severity of neurodevelopmental abnormality determines the loss of brain reserve in schizophrenia. Unlike brain reserve, cognitive reserve in schizophrenia is not determined only by genetic/early neurodevelopmental abnormality. Cognitive reserve is more about functional efficiency; it is the ability to optimize performance through differential recruitment of brain networks and/or alternative cognitive strategies. Genetic and early neurodevelopmental factors are still the most important, but not the only, determinant of cognitive reserve. Education, lifestyle and mental and physical activities modify the cognitive reserve through the neuroplasticity of our neural system throughout life (Fratiglioni et al. Reference Fratiglioni, Paillard-Borg and Winblad2004; Roe et al. Reference Roe, Xiong, Miller and Morris2007; Nithianantharajah & Hannan, Reference Nithianantharajah and Hannan2009). In patients with schizophrenia, brain reserve and cognitive reserve are low as a consequence abnormal neurodevelopment. However, cognitive reserve of schizophrenia patients is also modified by other factors, including family environment and socio-economical status, that can compensate for subtle neurodevelopmental abnormalities in some patients, such as those who have no apparent cognitive deficits. Some authors have suggested that cognitive reserve plays a role in differences in functional, clinical and cognitive outcomes of schizophrenia patients (Barnett et al. Reference Barnett, Salmond, Jones and Sahakian2006; Rund, Reference Rund2009; Leeson et al. Reference Leeson, Sharma, Harrison, Ron, Barnes and Joyce2011).
Neurodevelopmental abnormality (and low cognitive reserve) can influence the outcome of follow-up studies in several ways. First, lower baseline cognitive reserve would lead to less improvement in schizophrenia patients than in healthy controls, given that better baseline cognitive function is related to better practice effects (Rapport et al. Reference Rapport, Brines, Axelrod and Theisen1997). More importantly, neurodevelopmental abnormality is likely to be associated with temporary or permanent functional decline in response to a large number of events later in life. Dementia research clearly shows that people with high cognitive reserve are resilient to the effects of aging (Stern, Reference Stern2012) and it can be expected that aging and other factors can lead to non-schizophrenia-related cognitive decline or ineffective cognitive improvement in some patients with schizophrenia later in life. Such changes can have devastating effects on independent living skills in schizophrenia patients, who already have a severe pre-morbid cognitive dysfunction. However, the effect of these changes on functioning levels of patients with subtle neurodevelopmental abnormality might be more striking, given that these patients might have normal pre-morbid functioning.
Negative symptoms, cognitive reserve and functional decline before or after onset of psychosis in schizophrenia
A recent meta-analysis found that cognitive dysfunction in schizophrenia was stable in follow-up studies of prodrome and first-episode schizophrenia samples (Bora & Murray, Reference Bora and Murray2013). However, a subgroup of patients with schizophrenia has clear functional decline during a time period starting from a few years before onset of psychosis to a few years following the first episode (Kelley et al. Reference Kelley, Gilbertson, Mouton and van Kammen1992; Addington & Addington, Reference Addington and Addington2005; Foussias & Remington, Reference Foussias and Remington2010; Strauss et al. Reference Strauss, Allen, Miski, Buchanan, Kirkpatrick and Carpenter2012). This functional decline is associated with negative symptoms (Addington & Addington, Reference Addington and Addington1993; Brill et al. Reference Brill, Levine, Reichenberg, Lubin, Weiser and Rabinowitz2009) and its time-frame overlaps with the development of negative symptoms as these symptoms are commonly observed a few years before the first psychotic experiences, in prodrome and after the first episode of psychosis (Dominguez et al. Reference Dominguez, Saka, Lieb, Wittchen and van Os2010; Foussias & Remington, Reference Foussias and Remington2010; Cullen et al. Reference Cullen, Guimaraes, Wozniak, Anjum, Schulz and White2011). Patients with negative symptoms have significantly lower levels of pre-morbid functioning during late adolescence and greater pre-morbid deterioration between childhood and adolescence (Kelley et al. Reference Kelley, Gilbertson, Mouton and van Kammen1992). Deficit schizophrenia that presents with persistent negative symptoms is also characterized by significant functional impairment (Strauss et al. Reference Strauss, Allen, Miski, Buchanan, Kirkpatrick and Carpenter2012).
Interaction of neurodevelopmental cognitive impairment and neuroplastic changes leading to negative symptoms in schizophrenia can influence the level of functional decline. Although there is no obvious decline in raw scores of neuropsychological tests in longitudinal studies, negative symptoms probably impair learning and practice effects in schizophrenia. Therefore, it is expected that patients with negative symptoms would improve less in cognitive tasks at follow-up. In accordance with this view, our recent meta-analysis showed that persistence of negative symptoms was related to lack of cognitive improvement at follow-up (Bora & Murray, Reference Bora and Murray2013). Importantly, negative symptoms would be expected to influence learning abilities of patients with low cognitive reserve more than others. In addition, low cognitive reserve is more common in patients with negative symptoms (Harvey et al. Reference Harvey, Koren, Reichenberg and Bowie2006; Cohen et al. Reference Cohen, Saperstein, Gold, Kirkpatrick, Carpenter and Buchanan2007; Konstantakopoulos et al. Reference Konstantakopoulos, Ploumpidis, Oulis, Patrikelis, Soumani, Papadimitriou and Politis2011). The emergence of negative symptoms and their interaction with neurodevelopmental abnormality can explain a significant part of the functional decline observed before and after the first psychotic episode, even in patients who seemed to have had no previous functional deficits.
Neurodevelopment and medical co-morbidities, substance use and antipsychotics
Although pre-morbid neurodevelopmental abnormalities comprise the main factor leading to cognitive dysfunction in schizophrenia, the interaction of neurodevelopmental factors with numerous other factors also contributes to cognitive deficits in patients with established schizophrenia. Antipsychotics, including the second-generation antipsychotics (SGAs), clearly play a role in these cognitive deficits. Although antipsychotics can have both positive and negative effects (direct and/or indirect) on cognition in actively psychotic patients, their cognitive side-effects become clear once patients are stabilized. In recent studies, both dose reduction and guided discontinuation of SGAs were shown to lead to cognitive improvement in stable patients (Faber et al. Reference Faber, Smid, Van Gool, Wiersma and Van Den Bosch2012; Takeuchi et al. Reference Takeuchi, Suzuki, Remington, Bies, Abe, Graff-Guerrero, Watanabe, Mimura and Uchida2013). Several factors associated with cognitive dysfunction in healthy subjects, such as metabolic syndrome, chronic substance use and stress (Johnsen & Asbjørnsen, Reference Johnsen and Asbjørnsen2008; Panza et al. Reference Panza, Frisardi, Capurso, Imbimbo, Vendemiale, Santamato, D'Onofrio, Seripa, Sancarlo, Pilotto and Solfrizzi2010; Stavro et al. Reference Stavro, Pelletier and Potvin2013), are more common in schizophrenia and there is no doubt that they can contribute to cognitive impairment in schizophrenia. For example, some studies have shown that schizophrenia patients who have co-morbid metabolic syndrome, diabetes mellitus, hypertension, obesity, post-traumatic stress disorder (PTSD) and alcohol use disorder have more cognitive impairment than other patients without such co-morbidities (Goodman et al. Reference Goodman, Finkel, Naser, Andreyev, Segev, Kurs, Melamed and Bleich2007; Dickinson et al. Reference Dickinson, Gold, Dickerson, Medoff and Dixon2008; Fan et al. Reference Fan, Henderson, Nguyen, Cather, Freudenreich, Evins, Borba and Goff2008; Manning et al. Reference Manning, Betteridge, Wanigaratne, Best, Strang and Gossop2009; Friedman et al. Reference Friedman, Wallenstein, Moshier, Parrella, White, Bowler, Gottlieb, Harvey, McGinn, Flanagan and Davis2010; Lindenmayer et al. Reference Lindenmayer, Khan, Kaushik, Thanju, Praveen, Hoffman, Cherath, Valdez and Wance2012; Takayanagi et al. Reference Takayanagi, Cascella, Sawa and Eaton2012; Guo et al. Reference Guo, Zhang, Wei, Lv, Wu and Zhao2013). However, it is important to note that negative cognitive effects of some factors, such as cannabis use, can be difficult to demonstrate in schizophrenia because these factors can decrease the threshold and age of onset for FEP in people with less severe underlying neurobiological abnormality, leading to increased frequency of patients with better pre-morbid cognitive skills (Yücel et al. Reference Yücel, Bora, Lubman, Solowij, Brewer, Cotton, Conus, Takagi, Fornito, Wood, McGorry and Pantelis2012).
All of these vascular risk and substance use factors have been associated with white matter disruption in healthy controls and schizophrenia patients (Segura et al. Reference Segura, Jurado, Freixenet, Falcón, Junqué and Arboix2009; Brickman et al. Reference Brickman, Siedlecki, Muraskin, Manly, Luchsinger, Yeung, Brown, DeCarli and Stern2011; Hsu et al. Reference Hsu, Chen, Leu, Jaw, Lee, Tsai, Hsu, Bai and Leemans2012; Elofson et al. Reference Elofson, Gongvatana and Carey2013), and stress has been associated with hippocampal atrophy (Karl et al. Reference Karl, Schaefer, Malta, Dörfel, Rohleder and Werner2006). Such abnormalities would add to schizophrenia-related cerebral atrophy and white matter disruptions (Bora et al. Reference Bora, Fornito, Radua, Walterfang, Seal, Wood, Yücel, Velakoulis and Pantelis2011) and can explain the more pronounced cognitive dysfunction observed in schizophrenia patients with these co-morbidities. These structural changes can interact with neurodevelopmental abnormalities in the deterioration of functional and cognitive deficits; according to cognitive reserve theory, it can be argued that people with neurodevelopmental abnormalities are more susceptible to effects of these factors. Low cognitive reserve would influence the level of resilience of patients with schizophrenia and would lead to more severe permanent (i.e. vascular changes) and temporary (i.e. antipsychotics) cognitive impairment and functional decline.
Neurodevelopment and the aging brain in schizophrenia
Neurodevelopmental abnormalities can also interact with the aging process. People with neurodevelopmental syndromes do not age well. Dementia is up to five times more common in people with intellectual disabilities (Cooper, Reference Cooper1997; Strydom et al. Reference Strydom, Chan, King, Hassiotis and Livingston2013). Lower childhood cognitive ability is a risk factor for dementia in old age (McGurn et al. Reference McGurn, Deary and Starr2008). People with milder neurodevelopmental abnormalities are also vulnerable to the effects of aging. In a recent study, it was shown that asymptomatic carriers of Fragile X syndrome have a higher risk for development of late-onset dementia (Tassone et al. Reference Tassone, Greco, Hunsaker, Seritan, Berman, Gane, Jacquemont, Basuta, Jin, Hagerman and Hagerman2012). Therefore, it should be expected that the interaction of aging with manifest and latent neurodevelopmental abnormalities would lead to further loss of functioning in some patients with schizophrenia.
Whether schizophrenia patients have accelerated decline by age is the subject of controversy. Some authors support accelerated age-related decline in schizophrenia but others do not (Friedman et al. Reference Friedman, Harvey, Kemether, Byne and Davis1999; Harvey, Reference Harvey2001; Rajji & Mulsant, Reference Rajji and Mulsant2008; Jeste et al. Reference Jeste, Wolkowitz and Palmer2011; Irani et al. Reference Irani, Kalkstein, Moberg and Moberg2011; Shah et al. Reference Shah, Qureshi, Jawaid and Schulz2012). Importantly, the meta-analysis of Irani et al. (Reference Irani, Kalkstein, Moberg and Moberg2011) found that cognition did not change significantly at follow-up in old-aged patients with schizophrenia. However, it is important to note that, in old-aged patients, there was no cognitive improvement; in fact there was a marginal (and non-significant) change in the negative direction (d = –0.1), rather than a positive change as found in meta-analyses of follow-up studies in younger patients. In another study including 201 older-aged schizophrenia patients, there was evidence of more rapid cognitive decline in a subgroup of patients in comparison to controls and other patients (Thompson et al. Reference Thompson, Savla, Vahia, Depp, O'Hara, Jeste and Palmer2013). These patients had severe negative symptoms and were more likely to be living in a board-and-care facility. Lifetime poor functioning has also been associated with such changes (Friedman et al. Reference Friedman, Harvey, Kemether, Byne and Davis1999). These findings suggest that, although most people with schizophrenia and healthy subjects have a similar trajectory of age-related cognitive changes, there might be a subgroup of older-aged schizophrenia patients with low cognitive reserve and severe negative symptoms whose cognitive and functional deficits worsen more significantly.
Conclusions
Most neurocognitive deficits in schizophrenia are neurodevelopmental in origin and are explained by continuing problems in acquisition during development (developmental lag and arrest) rather than loss of acquired skills. These cognitive deficits are reflections of various developmental abnormalities that also increase the risk of developing psychosis. Neurobiological heterogeneity of such developmental conditions is likely to be related to the severity of cognitive abnormalities and determines the first age that cognitive deficits become apparent. In individuals who have severe cognitive dysfunction apparent from early childhood, more severe neurodevelopmental abnormalities, such as problems in migration, gyrification and activity-independent, hard-wired connectivity, are more likely to be found. In most individuals with schizophrenia who have less pronounced cognitive deficits, the progressive aspects of later neurodevelopment, including activity-dependent fine-tuning of synaptic connectivity (myelination, synaptic remodeling/dendritic arborization) in high-level association cortices, are likely to be abnormal. Such abnormalities would also lead to a further developmental lag during adolescence in individuals who already have severe problems in earlier phases of neurodevelopment.
In some patients, the interaction of neurodevelopmental abnormality and low cognitive reserve with neuroplastic changes related to the development of negative symptoms, vascular risk factors, antipsychotic use and aging leads to further loss of functioning over the years. Studies investigating the relationship between developmental trajectories of cognitive skills, its brain imaging correlates and psychosis-risk genes are important to fully understand cognitive impairment in schizophrenia.
Declaration of Interest
None.
